MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $7.63 (182.41% upside)

Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HC WainwrightReiterated RatingBuy$9.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015RBC CapitalLower Price Target$7.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015MizuhoReiterated RatingNeutral$5.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2015JMP SecuritiesLower Price TargetMarket Outperform$12.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Canaccord GenuitySet Price TargetHold$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014Piper JaffrayDowngradeOverweight -> Neutral$14.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/2/2016Q1($0.20)($0.24)$1.62 million$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.26)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.28)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015($0.33)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.26)($0.24)$40.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.23)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.19)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.31)($0.19)($0.25)
Q2 20162($0.28)($0.23)($0.26)
Q3 20162($0.28)($0.22)($0.25)
Q4 20162($0.23)($0.23)($0.23)
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)
Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateHeadline
06/29/16 02:17 PMRecently Issued Stock Ratings For AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
06/28/16 07:15 AMCompany Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Completes Patient Enrollment in Remaining Phase 3 ... - Smarter Analyst
06/28/16 06:00 AMAcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain - [PR Newswire] - SAP302 is a single-arm, open-label study that enrolled 76 adult patients who presented in the emergency room with moderate-to-severe acute pain associated with trauma or injury. SAP303 is a multicenter, open-label study that enrolled 139 patients 40 years and older who had moderate-to-severe acute pain following a surgical procedure with general anesthesia or spinal anesthesia (except those who received intrathecal opioids).
06/27/16 02:27 PMToday's Watch List: Spherix Incorporated (NASDAQ:SPEX), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Agilent ... - KC Register
06/27/16 02:27 PMShares in Oversold Area: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/27/16 02:27 PMStock Touching a Recent Low: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/27/16 02:27 PMStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Joins Russell 3000 and Russell 2000 Indexes - Smarter Analyst
06/27/16 06:00 AMAcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes - [PR Newswire] - REDWOOD CITY, Calif., June 27, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company has joined the broad-market Russell 3000 and Russell 2000 Indexes according to the final membership lists posted June 24th, 2016. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10% of the total market capitalization of that index. Membership in the Russell 3000® Index includes automatic inclusion in the appropriate growth and style indexes.
06/25/16 10:04 AMStrong Sell Calls Recommendations For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0 - Investor Newswire
06/25/16 10:04 AMAnalyst's Stocks Ratings Trend: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) , Alimera Sciences, Inc. (NASDAQ:ALIM) - Street Updates
06/24/16 02:17 PMShares Dropping to a Recent Low: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/24/16 10:22 AMNew Broker Ratings For AcelRx Pharmaceuticals, Inc. (ACRX) - FTSE News
06/24/16 10:22 AMAcelRx Pharmaceuticals Inc. (ACRX) Drops 5.23% on June 22 - Equities.com
06/22/16 03:06 PMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/21/16 03:32 PMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -
06/20/16 02:16 PMAnalyst Views For The Week Ahead: AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
06/18/16 07:01 AMStrong Buy Calls Count For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 3 - Investor Newswire
06/10/16 02:17 PMTrend Of Rating Given To AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Investor Newswire
06/10/16 10:39 AMEarnings Surprise in Focus: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Investor Newswire
06/05/16 10:08 AMAfter Last Week What Do Analysts Think Of AcelRx Pharmaceuticals, Inc. (ACRX) - Share Trading News
06/03/16 10:44 AMAcelRx Pharmaceuticals, Inc. (ACRX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 08:13 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Stock Update & Estimates - Stock Tick Tock - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to post earnings of $-0.23 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 10:54 AMInsiders Are Gradually Buying AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - HNN - Insiders Are Gradually Buying AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)HNNAccording to the latest SEC filings, insiders at AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have increased their position in the stock by 16.48% over the past 6 months. Insiders now own 0.40% of total outstanding shares. There are both legal and ...and more »
06/02/16 06:00 AMAcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June - [PR Newswire] - REDWOOD CITY, Calif., June 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
06/01/16 08:19 PMNews Sentiment For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Investor Newswire - News Sentiment For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)Investor NewswireAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Average broker stands at 1.8 while it was 1.8 three months ago. The quarterly report of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) can be made public close to 2016-08-01. It is estimated by the recent ...and more »
06/01/16 02:17 PMTarget Price and Stock Performance Rundown for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - HNN - Target Price and Stock Performance Rundown for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)HNNDuring the latest trading session, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shares traded +0.87%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
05/31/16 07:59 PMStrong Sell Calls Count For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0 - Investor Newswire - Strong Sell Calls Count For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0Investor NewswireThe Sell calls on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) were 0. Two months earlier 3 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 2. The buy recommendations were 0 and sell calls count was 0.and more »
05/26/16 07:41 PMStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Results from Phase 3 Study of ARX‑04 - Smarter Analyst - Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Results from Phase 3 Study of ARX‑04Smarter AnalystAcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016. In the SAP301 study, ...
05/26/16 06:00 AMAcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory Abdominal Surgeries at Euroanaesthesia - [PR Newswire] - REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at ...
05/26/16 12:54 AMInsiders Are Gradually Buying AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Wall Street Hints and News - Insiders Are Gradually Buying AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have increased their position in the stock by 16.16% over the past 6 months. Insiders now own 0.40% of total outstanding shares. There are both legal and ...and more »
05/25/16 07:33 PMAcelRx Pharmaceuticals : New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140 - REDWOOD CITY, Calif., May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department for the treatment of acute pain.
05/24/16 07:42 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Costs Of Goods Sold Stands At $1.77 Millions - RealistInvestor.com - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Costs Of Goods Sold Stands At $1.77 MillionsRealistInvestor.comFor the fiscal ended 2015-12-31, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) comprehensive income was $-0.001 millions and for the quarter ended 2015-12-31, it was $-0.001 millions. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted $-24.399 ...and more »
05/24/16 02:35 PMStock Update (NASDAQ:ACRX): New Study of AcelRx Pharmaceuticals Inc Reveals Cost of Initial IV Opioid Dose in the ... - Smarter Analyst - Stock Update (NASDAQ:ACRX): New Study of AcelRx Pharmaceuticals Inc Reveals Cost of Initial IV Opioid Dose in the ...Smarter AnalystAcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department for the treatment of acute pain. Based on an analysis of over 7 million patients who ...and more »
05/24/16 06:00 AMNew Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140 - [PR Newswire] - REDWOOD CITY, Calif., May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department for the treatment of acute pain. The study was sponsored by AcelRx Pharmaceuticals, Inc. "We believe that the development of a rapidly absorbed, non-invasive analgesic for emergency department use could be advantageous from both a cost and patient-benefit standpoint.
05/20/16 02:33 PMSeaport Global Upgrades AcelRx Pharmaceuticals Inc to Buy - Trade Calls - Seaport Global Upgrades AcelRx Pharmaceuticals Inc to BuyTrade CallsBrokerage firm Seaport Global Upgrades its rating on AcelRx Pharmaceuticals Inc(NASDAQ:ACRX). The shares have been rated Buy. Previously, the analysts had a Accumulate rating on the shares. The rating by Seaport Global was issued on May 6, 2016.AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) One-Year Price Target Estimate At $6.90Enterprise Leaderall 3 news articles »
05/19/16 05:52 PMETF’s with exposure to AcelRx Pharmaceuticals, Inc. : May 19, 2016 -
05/18/16 02:29 PMAcelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Short Interest Decreased By 2.35% - Wall Street Hints and News - Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Short Interest Decreased By 2.35%Wall Street Hints and NewsThe Massachusetts-based Granahan Investment Management Inc Ma has invested 0.2% in the stock. Grt Capital Partners L.L.C., a Massachusetts-based fund reported 76,472 shares. Out of 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), ...and more »
05/18/16 12:47 AMRevenue Update on AcelRx Pharmaceuticals Inc(NASDAQ:ACRX) - Trade Calls - Revenue Update on AcelRx Pharmaceuticals Inc(NASDAQ:ACRX)Trade CallsAcelRx Pharmaceuticals Inc(NASDAQ:ACRX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 2, 2016. Company reported revenue of $3.02M. Analysts estimated a revenue of $1.62M. Earnings per ...and more »
05/17/16 02:34 PMBuy Calls Count For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0 - Investor Newswire - Buy Calls Count For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0Investor NewswireAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has a total of 3 Strong Buy recommendations and 0 Strong Sell calls as of 2016-05-16. One month ago, the count of strong buy ratings were 3 and strong sell ratings were 0. The mean analyst score was 1.8.and more »
05/17/16 12:46 PMAcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/14/16 12:58 AMAcelRx Pharmaceuticals Inc. (ACRX) Jumps 5.25% on May 13 - Equities.com - AcelRx Pharmaceuticals Inc. (ACRX) Jumps 5.25% on May 13Equities.comAcelRx Pharmaceuticals Inc. (ACRX) was among the biggest gainers on the Russell 2000 for Friday May 13 as the stock popped 5.25% to $3.21, representing a gain of $0.16 per share. Some 225,495 shares traded hands on 1,213 trades, compared with an ...and more »
05/11/16 02:43 PMPerformance Recap and Target Perspective on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)B.O.D.Y ConfidentialIn the latest trading session, shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) moved -0.63%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, ...and more »
05/11/16 02:43 PMAnalysts give average Rating of “Hold” to AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) - Washington News Wire - Web Breaking NewsAnalysts give average Rating of “Hold” to AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)Washington News WireAcelRx Pharmaceuticals logo AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has received an average rating of “Hold” from the eight research firms that are covering the stock, Analyst Ratings.Net reports. One investment analyst has rated the stock with a sell ...AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Receives Average Rating of "Hold" from AnalystsWeb Breaking NewsAcelRx Pharmaceuticals, Inc. (ACRX) Updated Analyst CoverageRisers & Fallersall 3 news articles »
05/10/16 07:46 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Is $-2.7084 Off Its 52-Week High - Investor Newswire - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Is $-2.7084 Off Its 52-Week HighInvestor NewswireThe technical analysis of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock indicates that it is trading $-0.2447 points away -7.1624% from its 50-day MA of $3.4163. It is trading $-0.6852 or -17.7669% away its 200-day MA of $3.8568. After the last ...
05/09/16 02:41 PMNext Weeks Broker Price Targets For AcelRx Pharmaceuticals, Inc. (ACRX) - Share Trading News - Next Weeks Broker Price Targets For AcelRx Pharmaceuticals, Inc. (ACRX)Share Trading News05/05/2015 – AcelRx Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 7 price target on the stock. 04/27/2015 – Global Hunter Securities began new coverage on AcelRx Pharmaceuticals, Inc ...and more »
05/06/16 06:00 AMAcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery - [PR Newswire] - REDWOOD CITY, Calif., May 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase ...
05/05/16 07:49 PMAverage Analyst Rating for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - B.O.D.Y Confidential - Average Analyst Rating for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.8 on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/05/16 12:55 AMBroker Roundup For AcelRx Pharmaceuticals, Inc. (ACRX) - Share Trading News - Broker Roundup For AcelRx Pharmaceuticals, Inc. (ACRX)Share Trading News12/17/2013 – AcelRx Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 16.5 price target on the stock. The share price of AcelRx Pharmaceuticals, Inc. (ACRX) was down -1.26% during the last trading ...Roth Capital Analysts Reduce Earnings Estimates for AcelRx Pharmaceuticals Inc (ACRX)Web Breaking Newsall 2 news articles »
05/04/16 02:40 PMAcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May - PR Newswire (press release) - AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in MayPR Newswire (press release)REDWOOD CITY, Calif., May 4, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today ...and more »
05/04/16 05:18 AMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.70
  • 50 Day Moving Average: $3.14
  • 200 Day Moving Average: $3.44
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $122.34M
  • Current Quarter EPS Consensus Estimate: $-0.89 EPS
Additional Links:
AcelRx Pharmaceuticals (NASDAQ:ACRX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha